Zynerba's stock on a high as cannabis-based drug succeeds in trial

(Reuters) – Zynerba Pharmaceuticals Inc said on Thursday its cannabis-derived gel to treat genetic disorder Fragile X syndrome succeeded in significantly reducing symptoms such as anxiety in a mid-stage study.


Source: Reuters Health News